Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 4/20 | 0.53 |
| ▸ | AAK1 | Q2M2I8 | 4/20 | 0.52 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.51 |
| ▸ | EGFR | P00533 | 8/20 | 0.51 |
| ▸ | ERBB2 | P04626 | 8/20 | 0.51 |
| ▸ | NQO2 | P16083 | 1/20 | 0.51 |
| ▸ | FECH | P22830 | 1/20 | 0.51 |
| ▸ | MYH14 | Q7Z406 | 1/20 | 0.51 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27155176 | 1.00 | KDR (0.53) | KDRAAK1MAP2K1EGFRERBB2 | |
| SCHEMBL21561488 | 0.92 | ERBB2 (0.53) | KDREGFRERBB2NQO2FECH | |
| SCHEMBL27153489 | 0.89 | ERBB2 (0.53) | EGFRERBB2NQO2FECHMYH14 | |
| SCHEMBL27150087 | 0.89 | ERBB2 (0.53) | EGFRERBB2NQO2FECHMYH14 | |
| SCHEMBL23096260 | 0.86 | ERBB2 (0.57) | EGFRERBB2NQO2FECHMYH14 | |
| SCHEMBL27155177 | 0.83 | EGFR (0.49) | KDREGFRERBB2NQO2FECH | |
| SCHEMBL21561554 | 0.83 | ERBB2 (0.54) | KDREGFRERBB2NQO2FECH | |
| Hydrochloric Acid SCHEMBL27154319 | 0.82 | EGFR (0.49) | KDREGFRERBB2NQO2FECH | |
| SCHEMBL21561486 | 0.82 | ERBB2 (0.58) | KDREGFRERBB2NQO2FECH | |
| SCHEMBL21561495 | 0.81 | ERBB2 (0.54) | EGFRERBB2NQO2FECHMYH14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4577549-A1 | COMPOUNDS AND METHODS FOR MODULATING HER2 | Iambic Therapeutics, Inc. (US) | 2025-07-02 | — | — | EP | disclosed |
| WO-2024044570-A1 | COMPOUNDS AND METHODS FOR MODULATING HER2 | IAMBIC THERAPEUTICS, INC. (US) | 2024-02-29 | — | — | WO | disclosed |